AzTrials
AzTrials

Metastatic Breast CancerPhase 1Breast49NCT03473639

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

A Phase 1 study testing Entinostat and Capecitabine in people with Metastatic Breast Cancer and Breast Cancer, run by University of Virginia at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC), in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Metastatic Breast Cancer, Breast Cancer
What is being tested?
Entinostat and Capecitabine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
2 sitesUnited States
Study dates
29 Jan 2019to 1 Nov 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Disease Characteristics by Dose Escalation Phase and Expansion Phase:
  • Part A: Dose Escalation Phase:
  • Patients must have a histologically confirmed diagnosis of stage IV invasive breast cancer.
  • Patients can have breast cancer with positive OR negative estrogen and progesterone receptor status. Patients must have negative HER-2 receptor status. Estrogen, progesterone, and HER2 receptor status must be assessed according to ASCO/CAP guidelines. ER or PR positivity is defined as ≥ 1% positive nuclear staining. HER-2 is negative if tumor testing shows: a) IHC negative (0 or 1+) or b) ISH negative using single probe or dual probe. If HER-2 IHC is 2+, ISH must be performed and negative. HER-2 equivocal is not eligible.
  • Part B: Expansion Phase:
  • Patients must have a histologically confirmed diagnosis of stage I-III invasive breast cancer.
Show all 33Show fewer
  • Patients with multifocal, multicentric, synchronous bilateral and primary inflammatory breast cancers are allowed.
  • Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant.
  • Multicentric disease is defined as more than one invasive cancer ≥ 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants.
  • Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes (axillary or intramammary) in at least one breast, diagnosed within 30 days of each other. NOTE: The tumor with the highest recurrence score should be used.
  • Patients can have breast cancer with positive OR negative estrogen and progesterone receptor status. Patients must have negative HER-2 receptor status. Estrogen, progesterone, and HER2 receptor status must be assessed according to ASCO/CAP guidelines. ER or PR positivity is defined as ≥ 1% positive nuclear staining. HER-2 is negative if tumor testing shows: a) IHC negative (0 or 1+) or b) ISH negative using single probe or dual probe. If HER-2 IHC is 2+, ISH must be performed and negative. HER-2 equivocal is not eligible.
  • Patients must have been treated with standard neoadjuvant chemotherapy with at least three cycles of taxane or anthracycline based regimen. Patients must be registered within 36 weeks after last dose of chemotherapy.
  • Patients must have histologically confirmed residual invasive carcinoma at the time of surgery (ypT1mi or greater) or positive lymph nodes (ypN0(itc) or greater).
  • Both Phases:
  • Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator.
  • ECOG Performance Status of 0-2.
  • Age ≥ 18 years.
  • Subject must have a life expectancy ≥ 6 months.
  • Adequate bone marrow function defined as follows:
  • Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
  • Platelets ≥ 100,000 cells/mm3
  • Hemoglobin ≥ 9 g/dl (Note: The use of transfusion to achieve Hgb ≥ 9 g/dl is acceptable)Serum creatinine ≤ 1.5 x institutional upper limit normal (IULN) OR GFR ≥60 mL/min for patient with creatinine levels >1.5× institutional ULN
  • Bilirubin ≤ 1.5 x IULN OR Direct Bilirubin ≤ULN for patients with total bilirubin levels >1.5×ULN
  • ALT and AST ≤ 2.5 IULN
  • Alkaline Phosphatase ≤ 2.5 IULN
  • If a female is of childbearing potential, she has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required.
  • If a patient is of childbearing potential the patient must agree to use effective contraception during the study and for 120 days after the last dose of study drug.
  • Non-childbearing potential is defined as (by other than medical reasons):
  • ≥45 years of age and has not had menses for >2 years
  • Amenorrheic for <2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation
  • Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug
  • Non-vasectomized males must agree to use adequate contraception for at least 120 days after the last dose of study drug Males must also abstain from sperm donations for at least 120 days after the last dose of study drug.
  • Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade ≤ 2 (except alopecia and Grade 3 neuropathy).

Who cannot join

  • Subjects who have had chemotherapy, biological therapy, immunological therapy, radiation therapy, or hormonal therapy within 3 weeks prior to first dose of study treatment.
  • Subjects who are unable or unwilling to discontinue use of prohibited medications.
  • Subject is unable or unwilling to participate in a study related procedure.
  • Subject is a prisoner.
  • Subject has evidence or history of an uncontrolled bleeding disorder. Patients with chronic bleeding disorders that are controlled with treatment or not clinically relevant are allowed.
  • Subjects with history of CNS disease including primary brain tumor, seizures not controlled with standard medical therapy, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of first dose of study treatment.
Show all 27Show fewer
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment AND enrolling in the metastatic dose escalation phase of present study only.
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:
  • Myocardial infarction or arterial thromboembolic events within 6 months prior to first dose of study treatment or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval > 470 msec.
  • Uncontrolled hypertension (defined as BP >160/100) or diabetes mellitus.
  • Another known malignancy that is progressing or requires active treatment.
  • Any prior history of other cancer within the 2 years prior to first dose of study treatment with the exception of adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ).
  • Active infection requiring systemic therapy.
  • Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.
  • Allergy to benzamide or inactive components of entinostat.
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  • Currently participating and receiving investigational therapy on another study. If prior participation in a study of an investigational agent/device, last dose of investigational therapy or use of an investigational device must be greater than 4 weeks from the first dose of study drug in the present study.
  • Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), due to concerns for potential drug-drug interactions with entinostat and anti-retroviral medications.
  • Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to study treatment. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • If female, is pregnant or breastfeeding.
  • The following medications are prohibited while the patient is receiving entinostat:
  • Any other HDAC Inhibitor, including valproic acid
  • DNA methyltransferase inhibitors
  • Any additional anticancer agents (excluding entinostat and capecitabine), such as chemotherapy, immunotherapy, targeted therapy, biological response modifiers, or endocrine therapy, will not be allowed, even if utilized as treatment of non-cancer indications.
  • Any investigational agents.
  • Radiation Therapy
  • Traditional herbal medicines; these therapies are not fully studied and their use may result in unanticipated drug-drug interactions that may cause or confound the assessment of toxicity.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • University of Virginia

    Charlottesville, Virginia, 22908

  • University of Rochester Medical Center

    Rochester, New York, 14642

Other trials in United States

About this study

The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC), in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy.

Read the detailed description

In order to identify the maximum dose that should be used in future participants, the first participants will start at a low dose of both drugs. If the participants on this dose level tolerate the treatment well without too many side effects, the next participants will receive a higher dose of one of the medications, and if those participants also tolerate the treatment well, then the drugs will continue to be increased with the next participants until a maximum dose that participants tolerate well is reached.

Participants in both groups will receive entinostat on days 1, 8, and 15 of each 21-day cycle and capecitabine on days 1-14 of each cycle. MBC participants may receive this treatment as long as they do not have disease progression or side effects that require them to stop study treatment while participants with high-risk BC after neo-adjuvant therapy will receive up to 8 cycles of study treatment as long as they do not have disease progression or side effects that require them to stop study treatment.

While participants are on study treatment, they will have regular physical exams and labs. After participants finish study treatment, they should be followed by their primary oncologist at least once a year. Study staff will also be in contact by phone at least once a year for 10 years.

Being tested
Entinostat, Capecitabine
Keywords
Residual invasive breast cancer, Metastatic breast cancer
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EntinostatDrug

    Also called SNDX-275

    In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.

  • CapecitabineDrug

    Also called Xeloda

    In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.

Study groups in NCT03473639
Study groupRoleWhat they receive
Entinostat and CapecitabineExperimentalDose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery. The dose combinations include: Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment.
Receives: Drug: Entinostat; Drug: Capecitabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identification of a maximum tolerated dose combination (MTDC) of entinostat and capecitabine

    This will be defined based on the number of "dose limiting toxicities" in participants at each dose level.

    Measured: During the first cycle of treatment (each cycle is 21 days) for each participant

  2. Frequency of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy

    Frequency of adverse events (AEs) in participants with high-risk BC after neo-adjuvant therapy at the determined MTDC.

    Measured: AEs from consent through 30 days following stopping study treatment. Study treatment-related serious adverse events (SAEs) anytime

  3. Severity (as graded with the Common Terminology Criteria for Adverse Events (CTCAE)) of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy

    Severity of adverse events (AEs) in participants with high-risk BC after neo-adjuvant therapy at the determined MTDC.

    Measured: AEs from consent through 30 days following stopping study treatment. Study treatment-related serious adverse events (SAEs) anytime

Secondary outcomes (5)

  1. Frequency of adverse events (AEs) in MBC participants at the determined MTDC.

    Adverse events (AEs) will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 in MBC participants at the determined MTDC.

    Measured: AEs from consent through 30 days following stopping study treatment. Study treatment-related serious adverse events (SAEs) anytime

  2. Disease-free survival (DFS)

    Disease-free survival (DFS) following combination therapy with entinostat and capecitabine

    Measured: Participants will be followed for up to 10 years following completion of study therapy

  3. Severity (as graded with the Common Terminology Criteria for Adverse Events (CTCAE)) of adverse events (AEs) in MBC participants

    Adverse events (AEs) will be graded via the CTCAE version 4.03 in MBC participants at the determined MTDC.

    Measured: AEs from consent through 30 days following stopping study treatment. Study treatment-related serious adverse events (SAEs) will be collected starting at consent and continuing for the life of the study.

  4. Frequency of adverse events (AEs) and dose-limiting toxicities (DLTs) in participants on both arms of the study at the determined MTDC.

    Adverse events (AEs) will be assessed via the CTCAE version 4.03 in participants on both arms of the study at the determined MTDC.

    Measured: DLTs will be identified during the 1st cycle (each cycle is 21 days) of study treatment. AEs from consent through 30 days following completion of treatment. Study treatment-related SAEs will be collected starting at consent through end of study

  5. Severity (as graded with the CTCAE) of adverse events (AEs) in participants on both arms of the study at the determined MTDC

    Adverse events (AEs) will be graded via the CTCAE version 4.03 in participants on both arms of the study at the determined MTDC.

    Measured: DLTs will be identified during the 1st cycle (each cycle is 21 days) of study treatment. AEs from consent through 30 days following completion of treatment. Study treatment-related SAEs will be collected starting at consent through end of study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2018
  2. Study start29 Jan 2019
  3. Primary completion2 Sep 2021
  4. Study completion1 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03473639
Sponsor's protocol ID
20218
Acronym
Breast49
Status last verified
Oct 2022
First submitted
14 Feb 2018
Last updated
1 Nov 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Millard T, Brenin C, Humphrey C, Dhakal A, Falkson C, Petroni G, Wages NA, Dillon P. A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer. Int J Breast Cancer. 2024 Feb 7;2024:5515966. doi: 10.1155/2024/5515966. eCollection 2024.

    PubMed 38356965

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Entinostat and Capecitabine in people with Metastatic Breast Cancer and Breast Cancer, run by University of Virginia at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 33 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Identification of a maximum tolerated dose combination (MTDC) of entinostat and capecitabine (time frame: During the first cycle of treatment (each cycle is 21 days) for each participant). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03473639, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in